Cosmos Health (NASDAQ: COSM) director receives 20,000-share equity award via RSU conversion

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cosmos Health Inc. director John James Hoidas received an award of 20,000 shares of common stock on May 19, 2026, converted from restricted stock units under the company’s 2024 & 2025 Omnibus Incentive Plan. The award was a compensation-related grant exempt under Rule 16b-3, bringing his direct holdings to 50,000 shares.

Insider Trade Summary

20,000 shares exercised/converted

Mixed 2 txns

Insider Hoidas John James

Role null

Type	Security	Shares	Price	Value
Conversion	Restricted Stock Unit	20,000	$0.00	--
Grant/Award	Common Stock, par value $.001	20,000	$0.283	$6K

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Common Stock, par value $.001 — 50,000 shares (Direct, null)

Footnotes (1)

Reflects the award of 20,000 shares of Common Stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.

Key Figures

Equity award: 20,000 shares Award price: $0.2830 per share Holdings after grant: 50,000 shares +3 more

6 metrics

Equity award 20,000 shares Common stock granted May 19, 2026

Award price $0.2830 per share Common stock grant to director

Holdings after grant 50,000 shares Director’s direct common stock position

RSUs converted 20,000 units Restricted Stock Units converted to common stock

RSU conversion price $0.0000 per share Conversion of RSUs into common stock

Plan reference 2024 & 2025 Omnibus Incentive Plan Source of grant and RSU award

Key Terms

Restricted Stock Unit, Omnibus Incentive Plan, Rule 16b-3

3 terms

Restricted Stock Unit financial

"The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Omnibus Incentive Plan financial

"pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3"

An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.

Rule 16b-3 regulatory

"in a transaction exempt under Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/11/2026 - 05:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoidas John James

(Last)

(First)

(Middle)

5 AG. GEORGIOU STR.

(Street)

PILEA

THESSALONIKI

TK57001

(City)

(State)

(Zip)

GREECE

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cosmos Health Inc. [ COSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $.001	05/19/2026	05/19/2026	A⁽¹⁾		20,000	A	$0.283	50,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽²⁾	05/19/2026	05/19/2026	C			20,000	05/19/2026	05/19/2036	Common Stock, par value $.001	20,000	$0	0	D

Explanation of Responses:

1. Reflects the award of 20,000 shares of Common Stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3.

2. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.

	/s/ John J. Hoidas	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Cosmos Health (COSM) report for John James Hoidas?

Cosmos Health reported that director John James Hoidas received 20,000 shares of common stock as an equity award. The shares came from vested restricted stock units under the 2024 & 2025 Omnibus Incentive Plan and were exempt under Rule 16b-3.

How many Cosmos Health (COSM) shares does John James Hoidas hold after this Form 4?

After the reported transactions, John James Hoidas directly holds 50,000 shares of Cosmos Health common stock. This reflects the addition of 20,000 shares granted on May 19, 2026, which were issued upon conversion of vested restricted stock units.

Was the Cosmos Health (COSM) insider transaction an open-market purchase or a grant?

The transaction was a grant and conversion, not an open-market purchase. Hoidas received 20,000 shares as an equity award and corresponding restricted stock units converted into common stock, all under the company’s 2024 & 2025 Omnibus Incentive Plan.

What is the role of restricted stock units in this Cosmos Health (COSM) Form 4?

The Form 4 shows 20,000 restricted stock units converting into 20,000 shares of common stock at a conversion price of $0.0000. These RSUs were granted and vested on May 19, 2026, as part of Cosmos Health’s 2024 & 2025 Omnibus Incentive Plan.

Under what plan was the Cosmos Health (COSM) equity award to John James Hoidas granted?

The 20,000-share award to John James Hoidas was granted under Cosmos Health’s 2024 & 2025 Omnibus Incentive Plan. Both the stock grant and the related restricted stock unit vesting were reported as transactions exempt from Section 16(b) under Rule 16b-3.

What price is shown for the Cosmos Health (COSM) stock award in the Form 4?

The Form 4 lists a transaction price of $0.2830 per share for the 20,000-share common stock award. The related restricted stock unit conversion into 20,000 underlying common shares is reported at a conversion price of $0.0000 per share in the derivative section.